ConSynance Therapeutics
Cambridge, United States· Est. 2021
Consynance Therapeutics is a Clinical-Stage Rare CNS Disease Company Focusing on Prader-Willi Syndrome (“PWS”).
Private Company
Total funding raised: $30M
About
Consynance Therapeutics is a Clinical-Stage Rare CNS Disease Company Focusing on Prader-Willi Syndrome (“PWS”).
Small Molecules
Funding History
2Total raised:$30M
Series A$25MMar 15, 2023
Seed$5MJun 15, 2021